Description: Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.
Home Page: www.piramalpharma.com
Piramal Ananta
Mumbai,
400 070
India
Phone:
91 22 3802 3000
Officers
| Name | Title |
|---|---|
| Ms. Nandini Ajay Piramal | Executive Chairperson |
| Mr. Vivek Valsaraj | President, CFO & Executive Whole-Time Director |
| Ms. Tanya Sanish | Company Secretary & Compliance Officer |
| Mr. Peter Daniel DeYoung | CEO of Piramal Global Pharma & Director |
| Vinay Agarwal | Senior Vice President of Operations |
| Mr. Gagan Borana | Head of Investor Relations & Sustainability |
| Sameer Penkar | Vice President of Marketing |
| Prashanth M. S. | Vice President of Sales |
| Mr. Vikram Duggal | Senior Vice President of Human Resources |
| Mr. Debashish Chakravorty | Executive Vice President of India & UK Formulations |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 656.25 |
| Price-to-Book MRQ: | 4.4575 |
| Price-to-Sales TTM: | 4.0563 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 6719 |